Skip to main content

Clinical trial CANFOUR

An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors

Organ Multiple
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 1/2
Academic trial Non
Sponsor Cantargia AB
EudraCT Identifier 2017-001111-36
Inclusion criteria Metastatic
Last update